University of Manchester: Interrupting the treatment of vulnerable people on immune-suppressing medicines, doubles their antibody response to COVID-19 booster vaccination

A major clinical trial, led by experts at the University of Nottingham working in partnership with Universities and NHS hospitals including the University of Manchester , has found that by interrupting the treatment of vulnerable people on long-term

Related Keywords

United Kingdom ,Manchester ,Brompton ,Medway ,Nottingham ,London ,City Of ,Jonathan Cook ,John Iredale ,Rosemary Boyton ,Andy Ustianowski ,Linkedin ,Twitter ,Honorary Consultant Rheumatologist At Nottingham University Hospitals ,Imperial College London ,Facebook ,Research Council ,University Of Oxford ,University Of Nottingham ,University Of Manchester ,Department Of Infectious Disease ,National Institute For Health ,National Infection Specialty ,Oxford Clinical Trials Research Unit ,Lung Division ,Vaccine Research Programme ,Care Research ,Queen Mary University London ,Vaccine Response On Off Methotrexate ,National Institute ,Medical Research ,Queen Mary University ,Lancet Respiratory ,Professor Abhishek ,Honorary Consultant Rheumatologist ,Nottingham University Hospitals ,Research Programme ,Joint National Infection Specialty Lead ,Honorary Clinical Chair ,Professor Rosemary Boyton ,Respiratory Medicine ,Infectious Disease ,Royal Brompton Hospital ,Associate Professor Jonathan Cook ,Executive Chair ,Medical Research Council ,